title: Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries.
abstract: BACKGROUND
  Arterial injury after percutaneous transluminal coronary angioplasty (PTCA) triggers acute thrombus formation and thrombin generation. Hirudin, a potent and direct thrombin inhibitor, prevents thrombus formation after arterial injury. Two large clinical trials showed marked reduction in acute clinical events but no long-term benefits in reducing restenosis during short-term administration of thrombin inhibitors. Our hypothesis is that adequate, maintained thrombin inhibition, by inhibiting all the thrombin-dependent mechanisms, will reduce neointima formation after PTCA.
  
  
  RESULTS
  Thirty-six pigs received three different regimens of hirudin: bolus (1 mg/kg), short-term (bolus + 0.7 mg/kg per day for 2 days), and long-term (bolus + 0.7 mg/kg per day for 14 days). The results on neointima formation at 4 weeks after coronary angioplasty were compared with the control group (100 IU heparin/kg bolus). Hirudin was continuously administered for 2 weeks through an infusion pump. In vivo thrombin generation was persistently increased up to 2 weeks after angioplasty. Inhibition of thrombin activity for 14 days reduced luminal narrowing by 40% (58+/-3% versus 35+/-3%; P<.001). No differences were observed among the bolus and short-term hirudin groups and the control group.
  
  
  CONCLUSIONS
  Our results indicate that there is a continued, marked thrombin generation that lasts for at least 2 weeks after PTCA. Administration of r-hirudin for 2 weeks significantly reduces neointima formation after PTCA. This observation, if extrapolated to humans, could explain the lack of effect on restenosis observed in the clinical trials with antithrombin agents despite the clear benefits on reducing acute thrombotic complications after PTCA. Therefore an adequate and prolonged administration of thrombin inhibitors is needed to "passivate" the thrombogenic substrate (disrupted arterial wall) and achieve full benefit of this therapeutic approach.
authors.affiliation: Cardiovascular Biology Research Laboratory, Mount Sinai School of Medicine, New York, NY, USA.
authors.forename: R
authors.initials: R
authors.lastname: Gallo
authors.forename: A
authors.initials: A
authors.lastname: Padurean
authors.forename: V
authors.initials: V
authors.lastname: Toschi
authors.forename: J
authors.initials: J
authors.lastname: Bichler
authors.forename: J T
authors.initials: JT
authors.lastname: Fallon
authors.forename: J H
authors.initials: JH
authors.lastname: Chesebro
authors.forename: V
authors.initials: V
authors.lastname: Fuster
authors.forename: J J
authors.initials: JJ
authors.lastname: Badimon
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D000818:Animals; D000991:Antithrombins / Q000378:metabolism / Q000494:pharmacology; D003327:Coronary Disease / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D003331:Coronary Vessels / Q000187:drug effects / Q000293:injuries* / Q000473:pathology; D006629:Hirudins / Q000097:blood / Q000494:pharmacology; D010314:Partial Thromboplastin Time; D011994:Recombinant Proteins / Q000097:blood / Q000494:pharmacology; D012008:Recurrence; D013552:Swine; D013917:Thrombin / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D000991:Antithrombins; D006629:Hirudins; D011994:Recombinant Proteins; D013917:Thrombin